Electroencephalographic and behavioral convulsant effects of hydrobromide and hydrochloride salts of bupropion in conscious rodents

Neuropsychiatric Disease and Treatment

Volumn 5, Issue 1, 2009, Pages 189-206

  Henshall, David C ^a   Dürmüller, Nick ^b   White, H Steve ^c   Williams, Robert ^d   Moser, Paul ^b   Dunleavy, Mark ^a   Silverstone, Peter H ^e  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b Porsolt and Partners Pharmacology   (France)

^c NeuroAdjuvants Inc ^*  (United States)

^d Agenda Communications and Conference Services   (Ireland)

^e Biovail Corporation   (Canada)

Author keywords

Bupropion hydrobromide; Bupropion hydrochloride; EEG; Mice; Motor impairment; Rats; Seizures

Indexed keywords

AMFEBUTAMONE; BROMIDE; CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR DISORDER; BRAIN CORTEX; BRAIN ELECTROPHYSIOLOGY; BRAIN INJURY; CONTROLLED STUDY; CONVULSION; DISEASE DURATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG FORMULATION; DRUG INDICATION; DRUG MEGADOSE; ELECTROENCEPHALOGRAPHY; FEMALE; HIPPOCAMPUS; MALE; MOUSE; NONHUMAN; RAT; SEIZURE;

EID: 70449699758     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. GlaxoSmithKline. Wellbutrin® (bupropion hydrochloride) tablets product monograph, July 2006.
2. Peck AW, Stern WC, Watkinson C. Incidence of seizures during treatment with tricyclic antidepressant drugs and bupropion. J Clin Psychiatry. 1983;44:197-201.
3. Van Wyck Fleet J, Manberg PJ, Miller LL, et al. Overview of clinically significant adverse reactions to bupropion. J Clin Psychiatry. 1983;44:191-196.
4. Davidson J. Seizures and bupropion: a review. J Clin Psychiatry. 1989;50:256-261.
5. Johnston JA, Lineberry CG, Ascher JA, et al. A 102-center prospective study of seizure in association with bupropion. J Clin Psychiatry. 1991;52:450-456.
6. Dunner DL, Zisook S, Billow AA, Batey SR, Johnston JA, Ascher JA. A prospective safety surveillance study for bupropion sustained-release in the treatment of depression. J Clin Psychiatry. 1998;59:366-373. (Pubitemid 28373103)
7. Tutka P, Barczynski B, Wielosz M. Convulsant and anticonvulsant effects of bupropion in mice. Eur J Pharmacol. 2004;499:117-120. (Pubitemid 39201218)
8. Tutka P, Mroz T, Klucha K, Piekarczyk M, Wielosz M. Bupropion-induced convulsions: preclinical evaluation of antiepileptic drugs. Epilepsy Res. 2005;64:13-22. (Pubitemid 40726161)
9. Data on file. Biovail Study No. B06-802PK-10121. A two-way, crossover, fasting, steady-state dosage strength proportionality study of bupropion hydrobromide XL tablets (522 mg vs 3 x 174 mg) in normal healthy non-smoking adult volunteers. Chantilly, VA: Biovail Technologies, Ltd.; 2007.
10. Meeting of the Royal Medical and Chirurgical society of London, May 11, 1857. Lancet. 1857;1:527-528.
11. Friedlander WJ. The rise and fall of bromide therapy in epilepsy. Arch Neurol. 2000;57:1782-1785.
12. Ryan M, Baumann RJ. Use and monitoring of bromides in epilepsy treatment. Pediatr Neurol. 1999;21:523-528. (Pubitemid 29366818)
13. Araki T, Simon RP, Taki W, Lan JQ, Henshall DC. Characterization of neuronal death induced by focally evoked limbic seizures in the C57BL/6 mouse. J Neurosci Res. 2002;69:614-621. (Pubitemid 34966874)
14. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol. 1992;119:493-501.
15. Lucassen PJ, Chung WC, Vermeulen JP, Van Lookeren Campagne M, Van Dierendonck JH, Swaab DF. Microwave-enhanced in situ end-labeling of fragmented DNA: parametric studies in relation to postmortem delay and fixation of rat and human brain. J Histochem Cytochem. 1995;43:1163-1171.
16. Schmued LC, Albertson C, Slikker W Jr. Fluoro-Jade: a novel fluorochrome for the sensitive and reliable histochemical localization of neuronal degeneration. Brain Res. 1997;751:37-46. (Pubitemid 27122134)
17. Schmued LC, Hopkins KJ. Fluoro-Jade: novel fluorochromes for detecting toxicant-induced neuronal degeneration. Toxicol Pathol. 2000;28:91-99.
18. Schmued LC, Hopkins KJ. Fluoro-Jade B: a high affinity fluorescent marker for the localization of neuronal degeneration. Brain Res. 2000;874:123-130.
19. Mullen RJ, Buck CR, Smith AM. NeuN, a neuronal specific nuclear protein in vertebrates. Development. 1992;116:201-211.
20. Murphy B, Dunleavy M, Shinoda S, et al. Bcl-w protects hippocampus during experimental status epilepticus. Am J Pathol. 2007;171:1258-1268. (Pubitemid 47582899)
21. Hatazaki S, Bellver-Estelles C, Jimenez-Mateos EM, et al. Microarray profile of seizure damage-refractory hippocampal CA3 in a mouse model of epileptic preconditioning. Neuroscience. 2007;150:467-477. (Pubitemid 350198718)
22. Dürmüller N, Scherschlicht R, Porsolt RD. Vigilance-controlled quantified EEG in safety pharmacology. Current Protocols in Pharmacology Unit. 2000;10.6.
23. Racine RJ. Modification of seizure activity by electrical stimulation. II. Motor seizure. Electroencephalogr Clin Neurophysiol. 1972;32:281-294.
24. Paxinos G, Watson C, editors. The Rat Brain in Stereotaxic Coordinates. 5th Edition. Burlington, MA: Elsevier Academic Press; 2005.
25. Dunham MS, Miya TA. A note on a simple apparatus for detecting neurological deficit in rats and mice. J Am Pharm Assoc Am Pharm Assoc (Baltim). 1957;46:208-209.
26. Litchfield JT Jr, Wilcoxon F. A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther. 1949;96:99-113.
27. Finney DJ. Probit Analysis. 3rd Edition, London: Cambridge University Press; 1971.
28. Pozuelo-Utanda J, Crawford DC, Anderson JC. Bromism and epilepsy. Int J Neuropsychiatry. 1966;2:90-97.
29. Guidance for industry: ICH S7A Safety pharmacology studies for human pharmaceuticals (FDA, 2001).
30. Silverstone P, Williams R, McMahon L, Fleming R, Fogarty S. Alcohol significantly lowers the seizure threshold in mice when co-administered with bupropion hydrochloride. Ann Gen Psychiatry. 2008;7:11.
31. Pollard H, Cantagrel S, Charriaut-Marlangue C, Moreau J, Ben Ari Y. Apoptosis associated DNA fragmentation in epileptic brain damage. Neuroreport. 1994;5:1053-1055. (Pubitemid 24160511)
32. Pollard H, Charriaut-Marlangue C, Cantagrel S, Represa A, Robain O, Moreau J, Ben-Ari Y. Kainate-induced apoptotic cell death in hippocampal neurons. Neuroscience. 1994;63:7-18. (Pubitemid 24333948)
33. Sloviter RS, Dean E, Sollas AL, Goodman JH. Apoptosis and necrosis induced in different hippocampal neuron populations by repetitive perforant path stimulation in the rat. J Comp Neurol. 1996;366:516-533. (Pubitemid 26070617)
34. Bengzon J, Kokaia Z, Elmér E, Nanobashvili A, Kokaia M, Lindvall O. Apoptosis and proliferation of dentate gyrus neurons after single and intermittent limbic seizures. Proc Natl Acad Sci U S A. 1997;94:10432-10437. (Pubitemid 27407059)
35. Fujikawa DG, Shinmei SS, Cai B. Seizure-induced neuronal necrosis: implications for programmed cell death mechanisms. Epilepsia. 2000;41(Suppl 6):S9-S13. (Pubitemid 30692289)
36. Fujikawa DG, Shinmei SS, Cai B. Kainic acid-induced seizures produce necrotic, not apoptotic, neurons with internucleosomal DNA cleavage: implications for programmed cell death mechanisms. Neuroscience. 2000;98:41-53. (Pubitemid 30349142)
37. Henshall DC, Bonislawski DP, Skradski SL, Lan JQ, Meller R, Simon RP. Cleavage of bid may amplify caspase-8-induced neuronal death following focally evoked limbic seizures. Neurobiol Dis. 2001;8:568-580. (Pubitemid 32758661)
38. Henshall DC, Araki T, Schindler CK, et al. Activation of Bcl-2-associated death protein and counter-response of Akt within cell populations during seizure-induced neuronal death. J Neurosci. 2002;22: 8458-8465. (Pubitemid 35387586)
39. Bengzon J, Mohapel P, Ekdahl CT, Lindvall O. Neuronal apoptosis after brief and prolonged seizures. Prog Brain Res. 2002;135:111-119. (Pubitemid 35461010)
40. Liou AK, Clark RS, Henshall DC, Yin XM, Chen J. To die or not to die for neurons in ischemia, traumatic brain injury and epilepsy: a review on the stress-activated signaling pathways and apoptotic pathways. Prog Neurobiol. 2003;69:103-142. (Pubitemid 36398348)
41. Shinoda S, Schindler CK, Meller R, et al. Bim regulation may determine hippocampal vulnerability after injurious seizures and in temporal lobe epilepsy. J Clin Invest. 2004;113:1059-1068. (Pubitemid 38544128)